Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure

Cardiovascular Research

Volumn 60, Issue 3, 2003, Pages 478-487

  El Armouche, Ali ^a   Zolk, Oliver ^b   Rau, Thomas ^a   Eschenhagen, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Adenovirus; Beta adrenergic desensitization; Betablocker; G proteins; Heart failure

Indexed keywords

ADENYLATE CYCLASE; BETA ADRENERGIC RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN KINASE;

ADAPTATION; ADRENERGIC SYSTEM; DOWN REGULATION; GENE EXPRESSION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEMODYNAMICS; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ADENYLATE CYCLASE; ADRENERGIC BETA-ANTAGONISTS; CYCLIC AMP; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; SIGNAL TRANSDUCTION;

EID: 0345490696     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2003.09.014     Document Type: Review

References (98)

1. Bristow M.R., Ginsburg R., Minobe W.et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N. Engl. J. Med. 307:1982;205-211.
2. Harding S.E., MacLeod K.T., Jones S.M., Vescovo G., Poole-Wilson P.A. Contractile responses of myocytes isolated from patients with cardiomyopathy. Eur. Heart J. 12(Suppl. D):1991;44-48.
3. Hadcock J.R., Ros M., Watkins D.C., Malbon C.C. Cross-regulation between G-protein-mediated pathways. Stimulation of AC increases expression of the inhibitory G-protein, Gi alpha 2. J. Biol. Chem. 265:1990;14784-14790.
4. Ungerer M., Böhm M., Elce J.S., Erdmann E., Lohse M.J. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation. 87:1993;454-463.
5. Gilbert E.M., Olsen S.L., Renlund D.G., Bristow M.R. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 71:1993;23C-29C.
6. Neumann J., Schmitz W., Scholz H., von Meyerinck L., Döring V., Kalmar P. Increase of myocardial Gi-proteins in human heart failure. Lancet. 2:1988;936-937.
7. Feldman A.M., Cates A.E., Veazey W.B.et al. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J. Clin. Invest. 82:1988;189-197.
8. Böhm M., Gierschik P., Jakobs K.H.et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 82:1990;1249-1265.
9. Eschenhagen T., Mende U., Nose M., Schmitz W., Scholz H., Haverich A.et al. Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure. Circ. Res. 70:1992;688-696.
10. Morris A.J., Malbon C.C. Physiological regulation of G protein-linked signaling. Physiol. Rev. 79:1999;1373-1430.
11. Eschenhagen T. G proteins and the heart. Cell. Biol. Int. 17:1993;723-749.
12. Böhm M., Eschenhagen T., Gierschik P.et al. Radioimmunochemical quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J. Mol. Cell. Cardiol. 26:1994;133-149.
13. Mittmann C., Pinkepank G., Stamatelopoulou S.et al. Differential coupling of m-cholinoceptors to Gi/Go proteins in failing human myocardium. J. Mol. Cell. Cardiol. 35:2003;1241-1249.
14. 2+ channels in mouse heart. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1727-1732.
15. Ye C., Sowell M.O., Vassilev P.M., Milstone D.S., Mortensen R.M. Galpha(i2), Galpha(i3)and Galpha(o) are all required for normal muscarinic inhibition of the cardiac calcium channels in nodal/atrial-like cultured cardiocytes. J. Mol. Cell. Cardiol. 31:1999;1771-1781.
16. Vandecasteele G., Eschenhagen T., Scholz H., Stein B., Verde I., Fischmeister R. Muscarinic and beta-adrenergic regulation of heart rate, force of contraction and calcium current is preserved in mice lacking endothelial nitric oxide synthase. Nat. Med. 5:1999;331-334.
17. 2+ channel during cardiomyogenesis: switch from NO to AC-mediated inhibition. FASEB J. 13:1999;313-324.
18. Taussig R., Tang W.J., Hepler J.R., Gilman A.G. Distinct pattern of bidirectional regulation of mammalian ACs. J. Biol. Chem. 269:1994;6093-6100.
19. Bayewitch M.L., Avidor-Reiss T., Levy R.et al. Inhibition of AC isoforms V and VI by various Gbetagamma subunits. FASEB J. 12:1998;1019-1025.
20. Taussig R., Gilman A.G. Mammalian membrane-bound ACs. J. Biol. Chem. 270:1995;1-4.
21. Rhee S.G., Bae Y.S. Regulation of phosphoinositide-specific phospholipase C isozymes. J. Biol. Chem. 272:1997;15045-15048.
22. Tepe N.M., Liggett S.B. Transgenic replacement of type V AC identifies a critical mechanism of beta-adrenergic receptor dysfunction in the G alpha q overexpressing mouse. FEBS Lett. 458:1999;236-240.
23. Roth D.M., Bayat H., Drumm J.D., Gao M.H., Swaney J.S., Ander A.et al. AC increases survival in cardiomyopathy. Circulation. 105:2002;1989-1994.
24. Cohn J.N. The sympathetic nervous system in heart failure. J. Cardiovasc. Pharmacol. 14:1989;57-61.
25. Dzau V., Colucci W., Hollenberg N., Williams G. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 63:1981;645-656.
26. Ponicke K., Vogelsang M., Heinroth M.et al. Endothelin receptors in the failing and nonfailing human heart. Circulation. 97:1998;744-751.
27. Zolk O., Quattek J., Sitzler G.et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 99:1999;2118-2123.
28. Bayliss J., Norell M., Capena-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br. Heart J. 57:1987;17-21.
29. de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet. 362:2003;316-322.
30. Francis G.S., Goldsmith S.R., Ziesche S.M., Cohn J.N. Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am. J. Cardiol. 49:1982;1152-1159.
31. Francis G.S., Benedict C., Johnstone D.E.et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 82:1990;1724-1729.
32. Benedict C.R., Shelton B., Johnstone D.E.et al. Prognostic significance of plasma norepinephrine in patients in asymptomatic left ventricular dysfunction. Circulation. 94:1996;690-697.
33. Rundqvist B., Elam M., Bergmann-Sverrisdottir Y., Eisenhofer G., Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 95:1997;169-175.
34. Böhm M., La R.K., Schwinger R.H., Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J. Am. Coll. Cardiol. 25:1995;146-153.
35. Knape J.T., van Zwieten P.A. Positive chronotropic activity of angiotensin II in the pithed normotensive rat is primarily due to activation of cardiac beta 1-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 338:1988;185-190.
36. de Hurtado M.C., Alvarez B.V., Ennis I.L., Cingolani H.E. Stimulation of myocardial Na(+)-independent Cl(-)-HCO(3)(-) exchanger by angiotensin II is mediated by endogenous endothelin. Circ. Res. 86:2000;622-627.
37. Harada M., Itoh H., Nakagawa O.et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation. 96:1997;3737-3744.
38. Vogelsang M., Broede-Sitz A., Schafer E., Zerkowski H.R., Brodde O.E. Endothelin ETA-receptors couple to inositol phosphate formation and inhibition of adenylate cyclase in human right atrium. J. Cardiovasc. Pharmacol. 23:1994;344-347.
39. Anand-Srivastava M.B., Palaparti A. Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors. Can J. Physiol. Pharmacol. 81:2003;150-158.
40. Rose RA, Lomax AE, Giles WR. Inhibition of L-type calcium current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C mediated effect. Am J Physiol Heart Circ Physiol 2003 (in press).
41. Brehm B.R., Heinle H., Risler T., Wolf S.C. Chronically elevated endothelin-1 concentrations modulate the beta-adrenergic receptor system in vitro and in vivo. J. Cardiovasc. Pharmacol. 36:2000;S157-S159.
42. Feldman M.D., Copelas L., Gwathmey J.K.et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure. Circulation. 75:1987;331-339.
43. Böhm M., Beuckelmann D., Brown L.et al. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur. Heart J. 9:1988;844-852.
44. Schmitz W., Scholz H., Erdmann E. Effects of alpha- and beta-adrenergic agonists, phosphodiesterase inhibitors and adenosine on isolated human heart muscle preparations. TIPS. 8:1987;447-450.
45. Schwinger R.H., Böhm M., Mittmann C., La Rosee K., Erdmann E. Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium. J. Mol. Cell. Cardiol. 23:1991;461-471.
46. Näbauer M., Brown L., Erdmann E. Positive inotropic effects of the calcium channel activator Bay K 8644 on guinea-pig and human isolated myocardium. Naunyn-Schmiedeberg's Arch. Pharmacol. 337:1988;85-92.
47. Hajjar R.J., Gwathmey J.K. Cross-bridge dynamics in human ventricular myocardium: regulation of contractility in the failing heart. Circulation. 86:1992;1819-1826.
48. Neumann J., Bartel S., Eschenhagen T.et al. Dissociation of the effects of forskolin and dibutyryl cAMP on force of contraction and phospholamban phosphorylation in human heart failure. J. Cardiovasc. Pharmacol. 33:1999;157-162.
49. Harding S.E., Jones S.M., Vescovo G., Del Monte F., Poole-Wilson P.A. Reduced contractile responses to forskolin and a cyclic AMP analogue in myocytes from failing human ventricle. Eur. J. Pharmacol. 223(13):1992;39-48.
50. Piacentino V. III, Weber C.R., Chen X.et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ. Res. 92:2003;651-658.
51. Movsesian M.A., Smith C.J., Krall J., Bristow M.R., Manganiello V.C. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J. Clin. Invest. 88:1991;15-19.
52. Bethke T., Eschenhagen T., Klimkiewicz A.et al. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. Arzneimittelforschung. 42:1992;437-445.
53. Hershberger R.E., Anderson F.L., Bristow M.R. Vasoactive intestinal peptide receptor in failing human ventricular myocardium exhibits increased affinity and decreased density. Circ. Res. 65:1989;283-294.
54. Bristow M.R., Hershberger R.E., Port J.D., Minobe W., Rasmussen R. β1- and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol. Pharmacol. 35:1989;295-303.
55. Brown L.A., Harding S.E. The effect of pertussis toxin on beta-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. Br. J. Pharmacol. 106:1992;115-122.
56. Kompa A.R., Gu X.H., Evans B.A., Summers R.J. Desensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins. J. Mol. Cell. Cardiol. 31:1999;1185-1201.
57. Post S.R., Hammond H.K., Insel P.A. Beta-adrenergic receptors and receptor signaling in heart failure. Annu. Rev. Pharmacol. Toxicol. 39:1999;343-360.
58. Brodde O.E. Pathophysiology of the beta-adrenoceptor system in chronic heart failure: consequences for treatment with agonists, partial agonists or antagonists? Eur. Heart J. 12(Suppl. F):1991;54-62.
59. Schwinger R.H., Böhm M., Erdmann E. Evidence against spare or uncoupled beta-adrenoceptors in the human heart. Am. Heart J. 119:1990;899-904.
60. Engelhardt S., Böhm M., Erdmann E., Lohse M.J. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J. Am. Coll. Cardiol. 27:1996;146-154.
61. Koch W.J., Rockman H.A., Samama P.et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science. 268:1995;1350-1353.
62. Anand-Srivastava M.B. G-proteins and AC signalling in hypertension. Mol. Cell. Biochem. 157:1996;163-170.
63. Böhm M., Gierschik P., Knorr A., Schmidt U., Weismann K., Erdmann E. Cardiac AC, beta-adrenergic receptors, and G proteins in salt-sensitive hypertension. Hypertension. 22:1993;715-727.
64. Li Y., Anand-Srivastava M.B. Inactivation of enhanced expression of G(i) proteins by pertussis toxin attenuates the development of high blood pressure in spontaneously hypertensive rats. Circ. Res. 91:2002;247-254.
65. Gong H., Adamson D.L., Ranu H.K.et al. The effect of Gi-protein inactivation on basal, and beta(1)- and beta(2)AR-stimulated contraction of myocytes from transgenic mice overexpressing the beta(2)-adrenoceptor. Br. J. Pharmacol. 131:2000;594-600.
66. Communal C., Singh K., Sawyer D.B., Colucci W.S. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 100:1999;2210-2212.
67. Zaugg M., Xu W., Lucchinetti E., Shafiq S.A., Jamali N.Z., Siddiqui M.A. Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation. 102:2000;344-350.
68. Chesley A., Lundberg M.S., Asai T.et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase. Circ. Res. 87:2000;1172-1179.
69. 2-terminal kinase-dependent activation of the mitochondrial pathway. Circ. Res. 92:2003;136-138.
70. Sigmund M., Jakob H., Becker H.et al. Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 51:1996;127-132.
71. Rau T., Nose M., Remmers U.et al. Adenovirus-mediated overexpression of inhibitory G proteins suppresses β-adrenergic signaling in cardiac myocytes. FASEB. 17:2003;523-525.
72. Janssen P.M., Schillinger W., Donahue J.K.et al. Intracellular beta-blockade: overexpression of Galpha(i2) depresses the beta-adrenergic response in intact myocardium. Cardiovasc. Res. 55:2002;300-308.
73. Donahue J.K., Heldman A.W., Fraser H.et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat. Med. 6:2000;1395-1398.
74. Schütz W., Freissmuth M. Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol. Sci. 13:1992;376-380.
75. + currents in frog and rat cardiac cells. J. Physiol. 461:1993;743-765.
76. Xiao R.P., Ji X., Lakatta E.G. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol. Pharmacol. 47:1995;322-329.
77. Gong H., Sun H., Koch W.J.et al. Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation. 105:2002;2497-2503.
78. Hilf G., Gierschik P., Jakobs K.H. Muscarinic acetylcholine receptor-stimulated binding of guanosine 5′-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes. Eur. J. Biochem. 186:1989;725-731.
79. Laugwitz K.L., Offermanns S., Spicher K., Schultz G. mu and delta opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron. 10:1993;233-242.
80. Katada T., Bokoch G.M., Northup J.K., Ui M., Gilman A.G. The inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase: Properties and function of the purified protein. J. Biol. Chem. 259:1984;3568-3577.
81. Wong Y.H., Federman A., Pace A.M.et al. Mutant alpha subunits of Gi2 inhibit cyclic AMP accumulation. Nature. 351:1991;63-65.
82. Bristow M.R., Ginsburg R., Strosberg A., Montgomery W., Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J. Clin. Invest. 74:1984;212-223.
83. Yamada M., Inanobe A., Kurachi Y. G protein regulation of potassium ion channels. Pharmacol. Rev. 50:1998;723-760.
84. Lutz S., Mura R., Baltus D., Movsesian M., Kubler W., Niroomand F. Increased activity of membrane-associated nucleoside diphosphate kinase and inhibition of cAMP synthesis in failing human myocardium. Cardiovasc. Res. 49:2001;48-55.
85. Grimm M., Gsell S., Mittmann C.et al. Inactivation of (Gialpha) proteins increases arrhythmogenic effects of beta-adrenergic stimulation in the heart. J. Mol. Cell. Cardiol. 30:1998;1917-1928.
86. Akaishi Y., Hattori Y., Kanno M., Sakuma I., Kitabatake A. Agonist-independent tonic inhibitory influence of Gi on adenylate cyclase activity in rabbit ventricular myocardium and its removal by pertussis toxin: a role of empty receptor-mediated Gi activation. J. Mol. Cell. Cardiol. 29:1997;765-775.
87. Xiao R.P., Avdonin P., Zhou Y.Y.et al. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ. Res. 84:1999;43-52.
88. Heubach J.F., Rau T., Eschenhagen T., Ravens U., Kaumann A.J. Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3 adrenoceptor function in murine heart. Br. J. Pharmacol. 136:2002;217-229.
89. Matsui S., Fu M.L., Shimizu M.et al. Dilated cardiomyopathy defines serum autoantibodies against G protein coupled cardiovascular receptors. Autoimmunity. 21:1995;85-88.
90. Redfern C.H., Coward P., Degtyarev M.Y.et al. Conditional expression and signaling of a specifically designed Gi coupled receptor in transgenic mice. Nat. Biotechnol. 17:1999;165-169.
91. Van den Broek S.A., van Veldhuisen D.J., de Graeff P.A.et al. Mode of death in patients with congestive heart failure: comparison between possible candidates for heart transplantation and patients with less advanced disease. J. Heart Lung Transplant. 12:1993;367-371.
92. Saxon L.A., Stevenson W.G., Middlekauff H.R., Stevenson L.W. Increased risk of progressive hemodynamic deterioration in advanced heart failure patients requiring permanent pacemakers. Am. Heart J. 125:1993;1306-1310.
93. Kiuchi K., Shannon R.P., Komamura K.et al. Myocardial beta adrenergic receptor function during the development of pacing induced heart failure. J. Clin. Invest. 91:1993;907-914.
94. Li H.G., Jones D.L., Yee R., Klein G.J. Arrhythmogenic effects of catecholamines are decreased in heart failure induced by rapid pacing in dogs. Am. J. Physiol. 265:1993;H1654-H1662.
95. Eschenhagen T., Mende U., Diederich M.et al. Chronic treatment with carbachol sensitizes the myocardium to cAMP induced arrhythmia. Circulation. 93:1996;763-771.
96. Milano C.A., Allen L.F., Rockman H.A.et al. Enhanced myocardial function in transgenic mice overexpressing the β2 adrenergic receptor. Science. 264:1994;582-586.
97. Liggett S.B., Tepe N.M., Lorenz J.N.et al. Early and delayed consequences of β2 adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 101:2000;1707-1714.
98. Engelhardt S., Hein L., Wiesmann F., Lohse M.J. Progressive hypertrophy and heart failure in beta1 adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;7059-7064.